未知生产厂商
XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
XR5944 is a novel DNA targeting agent that in preclinical studies has demonstrated a high level of anti-tumor activity, both in vitro and in vivo, against a number of human tumor models. In human tumor xenograft models, treatment with XR5944 caused both partial and complete regression of large established tumors.
Investigated for use/treatment in solid tumors.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
